ESRRB and neoplasm: The orphan nuclear receptor NR2F6 (Nuclear Receptor subfamily2group F member 6) is an emerging therapeutic target for cancer immunotherapy.Upregulation of NR2F6 expression in tumor cells has been linked toproliferation and metastasis, while in immune cells NR2F6 inhibitsantitumor T-cell responses.